Unlearn and Trace Neuroscience Collaborate to Enhance ALS Clinical Trials Unlearn®, a leader in AI-powered solutions for clinical trials, has announced a strategic collaboration with Trace Neuroscience, a biotechnology company specializing in genomic therapies for neurodegenerative diseases. This partnership is…
ENHERTU Phase 3 DESTINY-Gastric05 Trial Starts for Untreated HER2+ Advanced Gastric Cancer The first patient has been successfully dosed in the DESTINY-Gastric05 phase 3 trial, which aims to evaluate the efficacy and safety of ENHERTU® (trastuzumab deruxtecan) in combination with…
Lilly’s RNA Silencer Achieves Nearly 94% Reduction in Key Cardiovascular Biomarker Eli Lilly has made a groundbreaking advancement in cardiovascular medicine with its investigational small interfering RNA (siRNA) therapeutic, lepodisiran, which demonstrated a remarkable ability to reduce lipoprotein(a) [Lp(a)] levels…
BeiGene’s TEVIMBRA® Gets CHMP Nod for First-Line Lung Cancer Treatment BeiGene, Ltd., a global oncology company soon to be rebranded as BeOne Medicines Ltd., has announced a significant milestone in its efforts to expand cancer treatment options. The Committee for…
Merck’s SC Pembrolizumab Shows Noninferior PK to IV KEYTRUDA in Trial Merck, known as MSD outside of the United States and Canada, has presented the first data from the pivotal 3475A-D77 Phase 3 trial evaluating subcutaneous pembrolizumab in combination with…
Novotech Report Highlights Surge in siRNA Research with 150+ Clinical Trials (2020-2024) Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, has released its latest preclinical report exploring the rapidly evolving landscape of small interfering RNA…
Blue Lake Biotechnology’s Intranasal COVID-19 Vaccine Candidate Demonstrates Long-Lasting Immunity and Broad Protection Blue Lake Biotechnology, Inc., a clinical-stage biotechnology company specializing in intranasal vaccine development, along with its affiliate CyanVac LLC, recently published two pivotal preclinical studies in the…
Epicrispr Biotech Raises $68M for FSHD Epigenetic Therapy Trial Epicrispr Biotechnologies, a pioneering biotechnology company dedicated to developing curative therapies, has announced the successful first close of its Series B financing, securing $68 million. The funds will be used to…
CEL-SCI: Multikine Boosts Quality of Life by Up to 95% in Head & Neck Cancer Patients CEL-SCI Corporation (NYSE American: CVM) has recently announced the publication of new data from its Phase 3 study of Multikine* (Leukocyte Interleukin, Injection) in…
SCORPIO-PEP Phase 3: Ensitrelvir First Oral Antiviral to Prevent COVID-19 Post-Exposure Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) presented late-breaking scientific findings at the Conference of Retroviruses and Opportunistic Infections (CROI)…
City of Hope’s Phase 1 Trial Featured at SSO Annual Meeting City of Hope’s groundbreaking Phase 1 clinical trial has demonstrated promising results for patients suffering from colorectal and appendiceal cancer that has metastasized to the peritoneum. As one of…
Seismic Therapeutic Starts Phase 1 Trial of S-1117 for Antibody-Mediated Diseases Seismic Therapeutic, Inc., a machine learning-driven immunology company, has announced a significant milestone in its journey toward developing transformative therapies for autoimmune diseases. The company has dosed the first…